New Drugs and Clinical Research · global
Reducing Repeated Airway Surgeries: FDA Grants Accelerated Approval to Voceryq, the First Plasmid DNA Immunotherapy
For patients whose respiratory papillomas repeatedly grow back, one fewer surgery means one fewer disruption to daily life. A small trial of Voceryq offers the possibility of a year without surgery, but how long the benefit lasts still requires confirmation in postmarketing studies.
Surgical removal of papillomas from the airway can temporarily improve voice and breathing, but may not prevent recurrence. For patients with recurrent respiratory papillomatosis (RRP) who have spent years returning to the operating room, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Inovio’s Voceryq on October 30, 2026, to reduce the frequency of surgeries to remove papillomas in adults. This also marks the first U.S. approval of a plasmid DNA-based immunotherapy.
RRP is primarily caused by human papillomavirus (HPV) types 6 and 11. Lesions often occur in the larynx, particularly near the vocal cords. These usually benign growths can cause hoarseness and chronic cough and, in severe cases, interfere with breathing. Even after lesions are removed, the virus may remain in the tissue, leaving some patients in continued need of surgery for years.
Known as INO-3107 during development, Voceryq aims to enable the immune system to recognize and attack infected cells. The therapy contains two plasmid DNAs carrying genetic instructions for specific HPV proteins and the immune-modulating molecule IL-12, respectively. Administration requires the CELLECTRA 5PSP device, using intramuscular injection and brief electrical pulses to help DNA enter cells.
The approval was based on RRP-001, an open-label, multicenter trial that enrolled 32 adults. Of these, 26 had undergone at least three surgeries to remove papillomas in the year before treatment and were included in the efficacy analysis; the median number of surgeries in that preceding year was 4.5. In the first year after treatment, seven patients, or 27%, required no further surgery. Here, “complete response” means freedom from surgery during the observation period and cannot be interpreted as clearance of the virus or a cure for the disease.
These results provide a signal of a reduced surgical burden, but the efficacy analysis included a limited number of patients, and the study had no concurrent randomized control group, making it impossible to fully exclude factors such as natural fluctuations in the disease. The FDA therefore used the accelerated approval pathway, requiring subsequent confirmation of clinical benefit. Common adverse reactions include injection-site reactions, headache, fatigue, hypertension, nausea, and dizziness; the electroporation procedure may also cause brief muscle contractions and local pain.
The FDA approval letter requires a confirmatory study enrolling at least 50 adult and pediatric patients, tracking the need for surgery for at least three years after completion of treatment, and comparing the results with an appropriate external control or a scientifically justified threshold. A draft study protocol must be submitted by December 30, 2026, the study must be completed by December 30, 2031, and the final report is due by August 30, 2032. The inclusion of children in the study does not mean that this approval covers pediatric use.
Between approval and patients actually receiving treatment, supply arrangements and preparations by healthcare providers are still needed. On the day of approval, Inovio said it expected to begin accepting orders and shipping in approximately 60 days, with a full commercial launch in the first quarter of 2027. For patients, this development offers a new option for reducing repeated surgeries; whether it can deliver sustained symptom improvement and extend the time without surgery remains a question that subsequent studies must answer.